# BiCAR (glofitamab): what clinicians are saying

> 68 statements from 6 sources (2 videos, 2 posts, 2 papers), each linked to its source. Commentary checked Nov 17, 2026.

## Report

- Trial: A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
- NCT ID: NCT04703686
- Registry: https://clinicaltrials.gov/study/NCT04703686
- Sponsor: The Lymphoma Academic Research Organisation
- Phase: Phase 2
- Status: Completed
- Drugs tested: glofitamab plus obinutuzumab
- Indication: relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-17 UTC
- Last checked: 2026-11-17 UTC
- Release hash: c3337248fe54d1fb8fe75f1be4f1de4d820d44bd8c9c20aa21ce31600c484391

## Counts

- Commentary sources screened: 7
- Sources cited by verified statements: 6
- Verified statements: 68
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 0
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 3
- Speakers cited: 3
- Cited speakers with a verified identity: 1
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 0
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 0

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

BiCAR was favored in unattributed remarks for reducing delays to full-dose treatment, an argument about urgency rather than a claim of greater benefit from acceleration. A speaker describing a separate high-risk cohort considered accelerated glofitamab feasible but attributed less benefit and more toxicity to adverse patient features. That experience warrants caution about extending use rather than contradicting the trial’s safety findings; the speaker called for studies to identify who would benefit.

## Findings (titles)

- F1. Accelerated RO7082859 ramp-up: what speakers say
  - 18 statements from 1 speaker in 4 sources, 2 of them podcasts or videos.
  - No named clinician · accounts and unnamed speakers.
- F2. RO7082859 after CAR-T: a speaker welcomes its activity, but says work remains
  - 21 statements from 2 speakers in 5 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “say work remains”.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F3. Fast ramp-up in high-risk DLBCL: a speaker finds it feasible but asks who benefits
  - 15 statements from 1 speaker in 2 sources, 1 of them a podcast or video.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “ask who benefits”.
  - No named clinician · accounts and unnamed speakers.

1 of the 3 findings and 9 of the 68 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 18 | 10 | 4 | 1 | 3 |
| F2 | 21 | 13 | 5 | 2 | 5 |
| F3 | 15 | 4 | 2 | 1 | 5 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 2 | 2 | 3 | 4 | 18 | 3 | 2 podcasts and video, 2 publications |
| F2 | 10 | 2 | 0 | 2 | 7 | 21 | 4 | 2 posts and articles, 1 podcast or video, 2 publications |
| F3 | 3 | 1 | 8 | 2 | 1 | 16 | 0 | 1 podcast or video, 1 publication |

### Trial dimensions

- Primary endpoint: Overall Survival: no finding draws on it directly
- Secondary endpoints: F2 (2 shared claims)
- Population and setting: F1 (1 shared claims), F2 (3 shared claims)
- The comparison: F2 (3 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (1 shared claims)
- Design and conduct: F2 (1 shared claims)

## Abbreviations

- CAR-T: chimeric antigen receptor T-cell therapy
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 68 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 0 of the 3 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

8 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 2 | 1 |
| Population and setting | discussed | 4 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 3 | 1 |
| Safety and tolerability | discussed | 3 | 2 |
| Design and conduct | discussed | 2 | 1 |
| Accelerated ramp-up, treatment urgency and its unproven incremental benefit | discussed | 7 | 2 |
| Translation to high-risk, physician-selected practice | discussed | 11 | 1 |
| Bridging before CAR-T or transplantation | discussed | 2 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 23 statements · 34%** | | | |
| YouTube | 23 | 2 | 2 |
| **Posts · 4 statements · 6%** | | | |
| X threads | 2 | 1 | 4 |
| LinkedIn posts | 2 | 1 | 1 |
| **Primary sources · 41 statements · 60%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 41 | 2 | not screened |

- Screened window: 2021-06-02 to 2026-06-12
- Cited window: 2021-06-02 to 2025-12-09
- Retrieved: 2026-11-16

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
- Registry: NCT04703686 (https://clinicaltrials.gov/study/NCT04703686)
- Study IDs: BiCAR
- Sponsor: The Lymphoma Academic Research Organisation
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Completed
- Enrollment: 67 (actual)
- Start: 2021-03-30 (actual)
- Primary completion: 2023-01-10 (actual)
- Primary endpoint: Overall Survival (4 years)
- Intervention: Obinutuzumab (drug)
- Intervention: RO7082859 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on accelerated glofitamab dose escalation and cytokine release syndrome risk in relapsed or refractory lymphoma.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 51 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.
- Most substantive IACH remarks cannot be assigned to a named participant. They cannot be counted as additional independent speakers alongside named participants; Sarkozy's identifiable contribution is a brief affirmation.
- The social-media statements include relayed material. They do not establish the relayers' independent endorsement, and reposts do not establish additional clinical agreement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The mixed-histology ASH23 abstract summary, published DLBCL cohort and separate high-risk practice cohort are different populations. Their response, survival and toxicity figures should not be combined.
- Schedule descriptions differ across the panel, interview and publication. A full protocol and an exact regulatory label for the RO7082859 alias were not available for this edition, limiting independent reconciliation.
- The social-media posts and recordings reviewed do not directly assess BiCAR's own OS estimate or the choice of OS as the primary endpoint. The publication's treatment preference and methodological arguments are contextual interpretations, not evidence of independent HCP consensus.
- The external-control comparison does not establish causality or superiority over an individual salvage regimen or another bispecific; residual confounding and eligibility restrictions remain material.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-17 UTC: current edition
  - Routine maintenance: 2 fixes (tags):
    - 2026-11-17 UTC: taxonomy mapping corrected
    - 2026-11-17 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-17 UTC. No changes.

## Offer

- Size: Focused · 68 verified statements · none from confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/bicar-nct04703686/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=bicar-nct04703686

## Cite

Erudio Health. BiCAR (NCT04703686): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/bicar-nct04703686

## Questions

### How much does the BiCAR report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the BiCAR report cover?

68 statements from 6 sources (2 videos, 2 posts, 2 papers), each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the BiCAR report?

Its preview, yes: get_report_card({ "slug": "bicar-nct04703686" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the BiCAR report?

Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/bicar-nct04703686.json
- Markdown: https://www.erudio.com/reports/bicar-nct04703686.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/bicar-nct04703686/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "bicar-nct04703686"}`
